

data not shown). We utilized siRNAs to investigate the role of PARs, which could effectively reduce each PAR mRNA expression (Fig. 1C). We confirmed that transfection of the mixture of siRNAs for PAR_{1–3} could simultaneously reduce the expression of PAR_{1–3} (Fig. 1C). The upregulatory effect of RgpA on IL-8 production was reduced by knockdown of PAR_{1–3} (Fig. 1D). We also found that inhibition of PLC γ , a common mediator of PAR signaling, by U73122 abolished

RgpA-induced enhanced IL-8 production (Fig. 1E). Thus, the PAR–PLC γ pathway plays a crucial role in RgpA-induced enhanced activation of vascular endothelial cells.

3.2. RgpA activates Weibel-Palade body exocytosis

Because early endothelial activation involves degranulation of the endothelial cell-specific granules Weibel-Palade bodies




Fig. 1. Effect of RgpA on IL-8 production induced by *P. gingivalis* LPS or HKPG. (A, B) HUVECs were stimulated for 6 h with the indicated concentrations of LPS or HKPG (A) or with *E. coli* LPS (10 ng/ml), *P. gingivalis* LPS (1 $\mu\text{g/ml}$), Pam₃CSK₄ (0.5 $\mu\text{g/ml}$) or IL-1 β (1 ng/ml) (B) in the presence or absence of 200 nM RgpA. The amounts of IL-8 released into the media were measured by ELISA. Each value is the mean \pm SD ($n=3$) *vs control group, $P < 0.01$. (C) HUVECs were transfected with siRNA for PAR₁, PAR₂ or PAR₃ or together with these siRNAs. The expression levels of mRNAs of PAR₁, PAR₂ and PAR₃ were determined by quantitative RT-PCR *vs control group, $P < 0.01$. (D, E) HUVECs were transfected together with siRNAs for PAR₁, PAR₂ and PAR₃ (D) or pretreated for 30 min with 10 μM U73122 (E). Cells were then stimulated for 6 h with 1 $\mu\text{g/ml}$ *P. gingivalis* LPS or 10^8 cells/ml HKPG in the presence or absence of 200 nM RgpA. The amounts of IL-8 released into the media were measured by ELISA. Each value is the mean \pm SD ($n=3$) *vs control group, $P < 0.01$.

(WPBs) [13–15], we thought to determine whether RgpA-induced activation of vascular endothelial cells is affected by WPB exocytosis. We first examined whether RgpA could activate Weibel-Palade body exocytosis in HUVEC. Quantification of exocytosis was performed by measuring the amount of VWF, an essential constituent of WPBs. RgpA-induced VWF release in a similar manner to the calcium ionophore A23187 (Fig. 2A). The release of VWF occurred within 5 min and

continued for at least 60 min after stimulation (Fig. 2B). Presence of the cysteine protease inhibitor leupeptin greatly reduced induction of VWF release by RgpA but not that by A23187 (Fig. 2C), suggesting that RgpA-induced exocytosis depends on its protease activity.




Fig. 2. Induction of WPB exocytosis by RgpA. (A) HUVECs were stimulated for 1 h with RgpA at the indicated concentrations or with 10 μM A23187. (B) HUVECs were stimulated with 200 nM RgpA for the indicated periods. (C) HUVECs were stimulated for 1 h with 200 nM RgpA or 10 μM A23187 in the presence or absence of 2 μM leupeptin. The amounts of VWF released into the media were measured by ELISA. Each value is the mean ± SD ($n = 3$) *vs vehicle group, $P < 0.01$; †vs '0 min', $P < 0.01$; and ‡vs control group, $P < 0.01$.




Fig. 3. Regulatory mechanisms of RgpA-activated WPB exocytosis. (A) HUVECs transfected with siRNAs for PAR₁, PAR₂ or PAR₃ were stimulated for 1 h with 200 nM RgpA or 10 μM A23187. (B) HUVECs pretreated for 30 min with 10 μM U73122 were stimulated for 1 h with 200 nM RgpA. (C) HUVECs pretreated for 30 min with 20 μM BAPTA-AM were stimulated for 1 h with 200 nM RgpA. The amounts of VWF released into the media were measured by ELISA. Each value is the mean ± SD ($n = 3$) *vs control group, $P < 0.01$.

3.3. RgpA activates WPB exocytosis through the PAR–PLC γ pathway

We next examined whether RgpA-induced WPB exocytosis was mediated by PARs and PLC γ . As shown in Fig. 3A, transfection of respective PAR siRNA could significantly suppress RgpA-induced VWF release. Common regulated WPB exocytosis is activated through an increase in intracellular Ca²⁺ level after stimulation with various secretagogues [13,14]. In addition, PLC γ is known as a regulator of intracellular calcium release by the generation of inositol (1,4,5) triphosphate. We found that the PLC γ inhibitor U73122 decreased RgpA-induced VWF release (Fig. 3B). Furthermore, RgpA-induced VWF release was significantly suppressed by the cell-permeable Ca²⁺ chelator BAPTA-AM (Fig. 3C). Thus, RgpA activates intracellular Ca²⁺-dependent WPB exocytosis through the PAR–PLC γ pathway.

3.4. Effect of WPB components on *P. gingivalis*-induced inflammatory responses

We finally investigated whether released substances from WPB affect the RgpA-induced enhanced cell activation. Among known substances of WPB, we focused on the Tie-2

receptor ligand and Ang-2 because Ang-2 is known to enhance TNF- α -induced proinflammatory responses in HUVECs [16]. HUVECs expressed mRNA of Ang-2, but not that of another Tie-2 ligand Ang-1 (Fig. 4A). Stimulation with *P. gingivalis* LPS did not alter these expressions (Fig. 4A). Ang-2 protein was localized in granules (Fig. 4B). We found that recombinant Ang-2 added to the culture increased IL-8 production by *P. gingivalis* LPS (Fig. 4C). Furthermore, knockdown of Ang-2 suppressed IL-8 expression induced by *P. gingivalis* LPS (Fig. 4D). Thus, Ang-2 has a role to mediate the enhanced activation of endothelial cells.

4. Discussion

PARs play important roles in the regulation of several physiological and pathological effects, including coagulation, inflammation and vascular homeostasis [11,12,17]. We found that endothelial PARs were involved in RgpA induction of WPB exocytosis and regulation of endothelial cell activation. PAR-mediated responses in endothelial cells are known to be activated by thrombin. Thrombin stimulation elicits a capillary leak in vivo and increased endothelial monolayer permeability in vitro [18,19]. In addition, thrombin activates WPB exocytosis via PAR₁ or PAR₂ [20]. Thus, in a way similar to thrombin,




Fig. 4. Effect of Ang-2 on IL-8 production by *P. gingivalis* LPS. (A) Total RNA of HUVECs stimulated for 6 h with or without given concentrations of LPS was extracted for RT-PCR using specific primer sets for Ang-1 or Ang-2. The cDNA of Ang-1 and Ang-2 were used as templates for positive controls. (B) HUVECs were stained immunofluorescently with anti-Ang-2 antibody. Cell nuclei were stained with H \ddot{o} chst33342. (C) HUVECs were stimulated for 6 h or 12 h with 1 μ g/ml *P. gingivalis* LPS in the presence or absence of 200 ng/ml recombinant Ang-2. The amounts of IL-8 released into the media were measured by ELISA. Each value is the mean \pm SD ($n = 3$) *vs control group, $P < 0.01$. (D) HUVECs transfected with siRNA for Ang-2 were stimulated for 6 h with 1 μ g/ml *P. gingivalis* LPS. The expression level of IL-8 mRNA was determined by quantitative RT-PCR *vs control group, $P < 0.01$.




Fig. 5. Schematic of the effect of vesicle-associated RgpA on vascular endothelial cells.

RgpA may activate PAR signaling, leading to activation and promotion of leukocyte adhesion to the vascular endothelium, which links inflammation and coagulation in a variety of pathological settings.

P. gingivalis has a broad array of virulence factors as immunostimulatory compounds [21]. Several factors function as agonists for Toll-like receptor (TLR) 2 and TLR4 [22–25]. We found that IL-8 production not only by *P. gingivalis* LPS and HKPG but also by TLR4-agonistic *E. coli* LPS, TLR2-agonistic Pam₃CSK₄ and IL-1 β was upregulated by RgpA, suggesting the synergism of TLRs/IL-1R and PARs. Indeed, several recent studies have suggested that TLRs and PARs synergistically function in induction of proinflammatory responses [26,27]. The presence of gingipains at the site of *P. gingivalis* infection may affect responsiveness of the vascular endothelium to virulence factors from *P. gingivalis*.

WPB exocytosis induces release of storage compounds and may control local or systemic physiological and pathological effects, including leukocyte rolling, thrombus formation, vascular inflammation and angiogenesis. Storage components of WPBs have various vasoregulatory activities. We demonstrated that Ang-2 could regulate endothelial response to *P. gingivalis* (Fig. 4C). Ang-2 has been identified as a functional antagonist of Ang-1. Ang-2 sensitizes endothelial cells to TNF- α , thereby acting as a switch of vascular responsiveness towards inflammatory stimuli [16]. It has been suggested that diabetes, an important risk factor for periodontal disease, induces increase in Ang-2 transcription and expression [28]. Thus, Ang-2 released from WPBs may be an important determinant of the severity of periodontal diseases caused by *P. gingivalis* infection.

Our study proposes that *P. gingivalis* infection can modulate inflammatory responses of vascular endothelial cells through release of gingipains (Fig. 5). Such an effect may have a crucial role in the initiation and regulation of periodontitis.

Acknowledgements

This work was supported by the Grant-in-Aid for Young Scientists (B):18791363 to T.I. and the AGU High-Tech Research Center Project to T.N. provided by the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References

- [1] R.J. Genco, Host responses in periodontal diseases: current concepts, *J. Periodontol.* 63 (1992) 338–355.
- [2] S.C. Holt, T.E. Bramanti, Factors in virulence expression and their role in periodontal disease pathogenesis, *Crit. Rev. Oral Biol. Med.* 2 (1991) 177–281.
- [3] Z. Chen, J. Potempa, A. Polanowski, M. Wikstrom, J. Travis, Purification and characterization of a 50-kDa cysteine proteinase (gingipain) from *Porphyromonas gingivalis*, *J. Biol. Chem.* 267 (1992) 18896–18901.
- [4] T. Kadowaki, M. Yoneda, K. Okamoto, K. Maeda, K. Yamamoto, Purification and characterization of a novel arginine-specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of *Porphyromonas gingivalis*, *J. Biol. Chem.* 269 (1994) 21371–21378.
- [5] R. Pike, W. McGraw, J. Potempa, J. Travis, Lysine- and arginine-specific proteinases from *Porphyromonas gingivalis*. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins, *J. Biol. Chem.* 269 (1994) 406–411.
- [6] T. Imamura, R.N. Pike, J. Potempa, J. Travis, Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from *Porphyromonas gingivalis* induces vascular permeability enhancement through activation of the kallikrein/kinin pathway, *J. Clin. Invest.* 94 (1994) 361–367.
- [7] T. Imamura, J. Potempa, R.N. Pike, J.N. Moore, M.H. Barton, J. Travis, Effect of free and vesicle-bound cysteine proteinases of *Porphyromonas gingivalis* on plasma clot formation: implications for bleeding tendency at periodontitis sites, *Infect. Immun.* 63 (1995) 4877–4882.
- [8] T. Ino, M. Inomata, Y. Kanno, T. Matsuyama, M. Machigashira, Y. Izumi, T. Imamura, M. Nakashima, T. Noguchi, K. Matsushita, Arginine-specific gingipains from *Porphyromonas gingivalis* deprive protective functions of secretory leukocyte protease inhibitor in periodontal tissue, *Clin. Exp. Immunol.* 145 (2006) 545–554.
- [9] T. Ino, Y. Kanno, J.-I. Dohkan, M. Nakashima, M. Inomata, K.-I. Shibata, C.J. Lowenstein, K. Matsushita, Pathogen recognition by toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells, *J. Biol. Chem.* 282 (2007) 8134–8141.
- [10] A. Uehara, K. Muramoto, T. Imamura, K. Nakayama, J. Potempa, J. Travis, S. Sugawara, H. Takada, Arginine-specific gingipains from *Porphyromonas gingivalis* stimulate production of hepatocyte growth factor (scatter factor) through protease-activated receptors in human gingival fibroblasts in culture, *J. Immunol.* 175 (2005) 6076–6084.
- [11] P.J. O'Brien, M. Molino, M. Kahn, L.F. Brass, Protease activated receptors: theme and variations, *Oncogene* 20 (2001) 1570–1581.
- [12] S.R. Coughlin, Thrombin signalling and protease-activated receptors, *Nature* 407 (2000) 258–264.
- [13] C.J. Lowenstein, C.N. Morrell, M. Yamakuchi, Regulation of Weibel-Palade body exocytosis, *Trends Cardiovasc. Med.* 15 (2005) 302–308.
- [14] M.G. Rondaj, R. Bierings, A. Kragt, J.A. van Mourik, J. Voorberg, Dynamics and plasticity of Weibel-Palade bodies in endothelial cells, *Arterioscler. Thromb. Vasc. Biol.* 26 (2006) 1002–1007.
- [15] U. Fiedler, M. Scharpfenecker, S. Koidl, A. Hegen, V. Grunow, J.M. Schmidt, W. Kriz, G. Thurston, H.G. Augustin, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, *Blood* 103 (2004) 4150–4156.
- [16] U. Fiedler, Y. Reiss, M. Scharpfenecker, V. Grunow, S. Koidl, G. Thurston, N.W. Gale, M. Witzernath, S. Rousseau, N. Suttrop, A. Sobke, M. Herrmann, K.T. Preissner, P. Vajkoczy, H.G. Augustin, Angiopoietin-2 sensitizes endothelial cells to TNF- α and has a crucial role in the induction of inflammation, *Nat. Med.* 12 (2006) 235–239.
- [17] O. Dery, C.U. Corvera, M. Steinhoff, N.W. Bunnett, Proteinase-activated receptors: novel mechanisms of signaling by serine proteases, *Am. J. Physiol.* 274 (1998) C1429–C1452.
- [18] G. Cirino, C. Cicala, M.R. Bucci, L. Sorrentino, J.M. Maraganore, S.R. Stone, Thrombin functions as an inflammatory mediator through activation of its receptor, *J. Exp. Med.* 183 (1996) 821–827.
- [19] G.P. van Nieuw Amerongen, S. van Delft, M.A. Vermeer, J.G. Collard, V.W. van Hinsbergh, Activation of RhoA by thrombin in endothelial

- hyperpermeability: role of Rho kinase and protein tyrosine kinases, *Circ. Res.* 87 (2000) 335–340.
- [20] J.H. Cleator, W.Q. Zhu, D.E. Vaughan, H.E. Hamm, Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP, *Blood* 107 (2006) 2736–2744.
- [21] S.C. Holt, L. Kesavalu, S. Walker, C.A. Genco, Virulence factors of *Porphyromonas gingivalis*, *Periodontol.* 2000 20 (1999) 168–238.
- [22] B.W. Bainbridge, S.R. Coats, R.P. Darveau, *Porphyromonas gingivalis* lipopolysaccharide displays functionally diverse interactions with the innate host defense system, *Ann. Periodontol.* 7 (2002) 29–37.
- [23] B.W. Bainbridge, R.P. Darveau, *Porphyromonas gingivalis* lipopolysaccharide: an unusual pattern recognition receptor ligand for the innate host defense system, *Acta Odontol. Scand.* 59 (2001) 131–138.
- [24] G. Hajishengallis, A. Sharma, M.W. Russell, R.J. Genco, Interactions of oral pathogens with toll-like receptors: possible role in atherosclerosis, *Ann. Periodontol.* 7 (2002) 72–78.
- [25] E. Burns, G. Bachrach, L. Shapira, G. Nussbaum, TLR2 is required for the innate response to *Porphyromonas gingivalis*: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption, *J. Immunol.* 177 (2006) 8296–8300.
- [26] A. Uehara, A. Iwashiro, T. Sato, S. Yokota, H. Takada, Antibodies to proteinase 3 prime human monocytic cells via protease-activated receptor-2 and NF- κ B for toll-like receptor- and NOD-dependent activation, *Mol. Immunol.* 44 (2007) 3552–3562.
- [27] S. Sugawara, A. Uehara, T. Nochi, T. Yamaguchi, H. Ueda, A. Sugiyama, K. Hanzawa, K. Kumagai, H. Okamura, H. Takada, Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells, *J. Immunol.* 167 (2001) 6568–6575.
- [28] H.P. Hammes, J. Lin, P. Wagner, Y. Feng, F. vom Hagen, T. Krzizok, O. Renner, G. Breier, M. Brownlee, U. Deutsch, Angiotensin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy, *Diabetes* 53 (2004) 1104–1110.

Synthesis and Characterization of a Dipalmitoylated Lipopeptide Derived from Paralogous Lipoproteins of *Mycoplasma pneumoniae*^{†‡}

Takeshi Into,^{1,‡*} Jun-ichi Dohkan,^{1,‡} Megumi Inomata,¹ Misako Nakashima,¹
Ken-ichiro Shibata,² and Kenji Matsushita¹

Department of Oral Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan,¹ and Laboratory of Oral Molecular Microbiology, Department of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan²

Received 28 January 2007/Accepted 12 February 2007

Genomic analysis of *Mycoplasma pneumoniae* revealed the existence of a large number of putative lipoprotein genes compared with the numbers in other bacteria. However, the pathogenic roles of *M. pneumoniae* lipoproteins are still obscure. In this study, we synthesized a lipopeptide (designated *M. pneumoniae* paralogous lipoprotein 1 [MPPL-1]) in which an *S*-dipalmitoylglyceryl cysteine was coupled to a peptide with a consensus sequence of a putative paralogous lipoprotein group characteristic of *M. pneumoniae*. The cytokine-inducing activity of MPPL-1 in human monocytic cells was much weaker (~700-fold weaker) than that of the known mycoplasma *S*-dipalmitoylated lipopeptide FSL-1 or MALP-2. MPPL-1 required Toll-like receptor (TLR2) to activate NF- κ B-dependent gene transcription in HEK293 cells, although a 1,000-fold-larger amount of MPPL-1 was needed to exert activity similar to that of FSL-1 in the cells. TLR2-mediated recognition of MPPL-1 was synergistically upregulated by TLR6 but not by TLR1 or TLR10, although the activity was still weak. In addition, MPPL-1 did not antagonize FSL-1 recognition in human monocytic cells and TLR2/TLR6-expressing HEK293 cells. Thus, these results suggest that there is preferential selective recognition of diacylated lipopeptides due to the magnitude of an affinity with TLR2 and TLR6 and the roles of increased paralogous lipoprotein genes of *M. pneumoniae* in evasion of TLR2 recognition.

Membrane-bound lipoproteins are thought to play important roles in the survival of bacteria through four main functions: a structural function, a transport function, an adhesion function, and an enzymatic function (7). Many lipoproteins have been identified in various species of bacteria and have been shown to comprise a framework structure containing a lipidated N-terminal cysteine residue coupled to distinct polypeptides. The maturation of bacterial lipoproteins generally comprises three steps; the first step involves diacylglyceryl modification of a cysteine residue by diacylglycerol transferase, the second step involves cleavage of the leader peptide by signal peptidase II, and the final step involves N acylation of the N-terminal diacylglyceryl cysteinyl residue, with which lipoproteins are synthesized as triacylated lipoproteins (7). It has also been shown that lipoproteins derived from *Rhodospseudomonas viridis* and several mycoplasma species do not undergo modification in the final step and are synthesized as diacylated lipoproteins (7).

In contrast to their crucial functions in the survival of bacteria, bacterial lipoproteins act as pathogenic substances to stimulate the immune systems of humans and animals through

the recognition receptors that monitor exogenous pathogens (3). Toll-like receptors (TLRs) are central pattern recognition receptors of the innate immune system that recognize a wide range of invading microorganisms through conserved chemical structures in their cells (34). TLR2 is essential for mediation of immune responses to the most diverse set of molecular structures of microbes, including peptidoglycans, lipoteichoic acids, porins, lipoarabinomannans, and lipoproteins/lipopeptides (21, 34). TLR2 forms heteromers with either TLR1 or TLR6, probably to discriminate the structures of molecular patterns, especially the N-terminal lipidated cysteinyl portions of bacterial lipoproteins as active sites (4, 29). TLR1 and TLR6 have been reported to be involved in simple discrimination of the difference between triacylated and diacylated lipoproteins/lipopeptides (36, 37). However, recent arduous work by several study groups has shown that such diverse potentials of TLR1 and TLR6 are largely dependent on more subtle structures of lipoproteins/lipopeptides, such as the length of an N-terminal fatty acid chain, the chirality of the central carbon of the diacylglycerol, and the charge of the C-terminal amino acids (5, 6, 28). It has been suggested that in addition to TLR1 and TLR6, TLR10, which is not encoded in the murine genome, is related to TLR2 recognition because of its sequence similarity and the possibility that it forms a heteromer with TLR2 (8, 12).

Mycoplasmas are microbes in regressive evolution and differ from other microbes in many respects. For example, they completely lack a cell wall, and their bilipid membrane is therefore the only structure that regulates interactions with the external environment (31). Some mycoplasmas cause severe respira-

* Corresponding author. Mailing address: Department of Oral Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morioka, Obu, Aichi 474-8522, Japan. Phone: 81-562-44-5651, ext. 5064. Fax: 81-562-46-8684. E-mail: into@nils.go.jp.

† Supplemental material for this article may be found at <http://iai.asm.org/>.

‡ T.I. and J.D. contributed equally to this work.

§ Published ahead of print on 26 February 2007.

tory, arthritic, and urogenital diseases in humans and animals. *Mycoplasma pneumoniae* is a human pathogen that causes "atypical pneumonia," particularly in older children and young adults (38). The genome size of *M. pneumoniae* is ~820 kb, and the genomic sequence has been completely analyzed (13, 14). Interestingly, a large number of putative lipoprotein-encoding genes have been identified in the genome (46 of 689 genes; 6.68%) compared with the numbers of such genes in the genomes of other microbes, such as *Escherichia coli* K-12 (22 of 4,243 genes; 0.52%) and *Bacillus subtilis* (26 of 4,105 genes; 0.63%) (7). Even in the closely related sister species *Mycoplasma genitalium*, only 21 putative lipoproteins (encoded by 477 genes; 4.4%) could be found. Despite the existence of such genetic data, little is known about the roles of lipoproteins in *M. pneumoniae* pathogenicity, although there has been much interest in the pathogenic roles of membrane lipoproteins of other mycoplasma species during infection because of their diverse functions, including adherence to host cells, antigenic variation, and TLR2- and TLR6-mediated immunostimulation (30).

In this study, we attempted to synthesize a lipopeptide having an *S*-(2,3-bisphosphatidyl)-cysteine residue coupled to an N-terminal consensus peptide of *M. pneumoniae*-specific lipoproteins encoded by paralogous genes. Interestingly, the level of immunostimulatory activity of this lipopeptide was much lower than that of the known mycoplasma lipopeptide MALP-2 or FSL-1 despite the structural uniformity. We also investigated the recognition of this lipopeptide by TLRs.

MATERIALS AND METHODS

Preparation of synthetic lipopeptides. The synthetic lipopeptides FSL-1 and MALP-2 were prepared as described previously (17). *S*-(2,3-bisacyloxypropyl)-cysteinyl TGIOADLRNLIK, designated *M. pneumoniae* paralogous lipoprotein 1 (MPPL-1), was synthesized using a method similar to the method used for synthesis of FSL-1 and MALP-2. Briefly, the side chain-protected sequence TGIOADLRNLIK was constructed with an automated peptide synthesizer (model 433; Applied Biosystems). (9-Fluorenylmethoxy carbonyl)-*S*-(2,3-bisphosphatidyl)-cysteine (Novabiochem) was manually coupled to the peptide resin by using a 1-hydroxy-7-azabenzotriazole-1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/CH₂Cl₂-dimethylformamide solvent system. The 9-fluorenylmethoxy carbonyl and resin were removed from the lipopeptide by using trifluoroacetic acid. The lipopeptide was extracted into 90% acetic acid, lyophilized, and purified by preparative high-pressure liquid chromatography with a reversed-phase C₁₈ column (30 by 250 mm). The level of purity of the lipopeptide was confirmed by analytical high-pressure liquid chromatography with a reversed-phase C₁₈ column (4.6 by 150 mm) to be 96%. All of the lipopeptides were used without separation of the *S*-form and *R*-form stereoisomers. The lipopeptides were dissolved in phosphate-buffered saline containing 10 mM *n*-octyl- β -glucopyranoside at a concentration 0.5 mM and stored at -80°C until they were used.

Cell culture. Dulbecco modified Eagle medium, RPMI 1640 medium, penicillin G, streptomycin, and trypsin-EDTA were obtained from Sigma. Human monocytic cell line THP-1 was cultured in RPMI 1640 medium as described previously (19). Human embryonic kidney HEK293 cells were grown in Dulbecco modified Eagle medium as described previously (18).

Determination of IL-6 and IL-8 by enzyme-linked immunosorbent assays (ELISA). A total of 1×10^5 THP-1 cells were stimulated for 12 h with various concentrations of mycoplasma lipopeptides, and the amounts of interleukin-6 (IL-6) and IL-8 released into the media were determined by using human IL-6 Cytoset and human IL-8 Cytoset (Invitrogen), respectively, according to the instructions of the manufacturer. The results described below are representative of three separate experiments, and the data are expressed as means and standard deviations.

DNA cloning. Plasmids encoding human TLR1, TLR2, and TLR6 have been described previously (18). Human TLR10 cDNA was obtained by reverse tran-

scription-PCR of RNA isolated from human umbilical vein endothelial cells and then cloned into a pEF6 vector (Invitrogen). The DNA sequences were confirmed by the dideoxy chain termination method by using an ABI Prism 3100 genetic analyzer.

Luciferase reporter gene assay. HEK293 cells were plated at a concentration of 0.5×10^5 cells per well in 24-well plates before transfection. The cells were transiently transfected with an NF- κ B-driven firefly luciferase reporter plasmid (pNF- κ B-Luc; Stratagene) and a construct directing expression of *Renilla* luciferase under the control of a constitutively active thymidine kinase promoter (pRL-TK; Promega) together with TLR-encoding plasmids. After 24 h of incubation, the cells were stimulated for 6 h with MPPL-1 or FSL-1 in media containing 1% fetal bovine serum. Then the cells were lysed, and the luciferase activity was measured using the Dual-Luciferase reporter assay system (Promega) according to instructions of the manufacturer. The results below, expressed as the means and standard deviations of values for triplicate wells, are representative of three separate experiments. The experiment using HEK293 cells stably expressing TLR2 has been described previously (20).

Statistics. All values were evaluated by statistical analysis using Student-Newman-Keuls test. Differences were considered to be statistically significant at a *P* value of <0.05.

RESULTS

Preparation of MPPL-1. Himmelreich et al. reported that 46 protein genes were identified as genes encoding putative lipoproteins in the *M. pneumoniae* M129 (=ATCC 29342) genome based on the following characteristic lipoprotein-specific features: (i) the presence of one or more basic amino acids among the first five to seven amino acids of the N terminus, (ii) the presence of a hydrophobic signal peptide, and (iii) the presence of a cysteine residue immediately downstream of the signal peptide (13). However, we found that 48 proteins had these lipoprotein signatures. The N-terminal lipoprotein moieties of all putative lipoproteins are shown in Table S1 in the supplemental material. The amino acid sequences of these lipoproteins are included in the data at a website (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=genome>), and the protein designations were based on the MPN numbering scheme described by Himmelreich et al. (13). Importantly, many of these putative lipoproteins have recently been confirmed to be functionally expressed in the microorganism (11, 33, 39). In addition to 48 putative lipoproteins, there are several proteins with high levels of similarity to the lipoproteins without the lipoprotein signature at the N terminus (13), but we did not include these proteins in the list.

Comparison of 30 amino acids of N-terminal lipoprotein moieties revealed that the *M. pneumoniae* lipoproteins include members of seven subgroups, which are probably groups of paralogous lipoproteins (see Table S1 in the supplemental material). We focused on group 1 composed of MPN011, MPN054, MPN271, MPN369, MPN411, MPN467, MPN650, and MPN654 because the N-terminal sequences of these putative lipoproteins could not be identified by a BLAST search in other known organisms, even the sister species *M. genitalium*, suggesting that the lipoprotein genes were propagated uniquely in the evolution of this microorganism. The sequence of MPN505 is also very similar to the sequences of these lipoproteins, but MPN505 lacks the lipoprotein signature. Importantly, the study of Hallamaa et al. showed that there was expression of mRNAs for all group 1 lipoproteins and the detectable proteins MPN271, MPN411, and MPN650 (11). Comparison of N-terminal sequences of these lipoproteins revealed that the levels of similarity of MPN271, MPN369,




FIG. 1. Synthesis of MPPL-1. (A) Alignment of putative paralogous lipoproteins. The N-terminal sequences of MPN011, MPN054, MPN271, MPN369, MPN411, MPN467, MPN650, and MPN654 were compared. The cysteine residue immediately downstream of the signal peptide is indicated by an asterisk. (B) Structure of MPPL-1.

MPN411, MPN467, and MPN654 are particularly high (Fig. 1A). These putative lipoproteins have a characteristic feature; namely, the C-terminal amino acid residue flanking the cysteine residue immediately downstream of the signal peptide is threonine, although the corresponding amino acid of common bacterial lipoproteins is glycine, alanine, or serine.

To analyze the pathological roles of this paralogous lipoprotein group, we attempted to synthesize a lipopeptide having an N-terminal sequence common to these lipoproteins. The results of previous work suggested that synthetic lipopeptides with original peptide sequences with more than 10 amino acids could mimic the immunostimulatory activity of natural lipoproteins (24, 27, 32). Therefore, we determined that the partial consensus sequence of MPN271, MPN369, MPN411, MPN467, and MPN654 is TGIQADLRNLIK, which should couple to an *S*-dipalmitoylglycerol cysteine. The structure was chemically synthesized using a method similar to the method used for synthesis of known mycoplasmal lipopeptides described previously (17, 32), and the protein was designated MPPL-1 (Fig. 1B). All of our preparations of mycoplasmal lipopeptides were synthesized as mixtures of the *S*-form and *R*-form stereoisomers.

Immunostimulatory activity of MPPL-1. To investigate the immunostimulatory activity of MPPL-1, we examined the induction of cytokine production in human monocytic THP-1 cells, comparing the activity of MPPL-1 with the activities of two synthetic mycoplasmal lipopeptides. MALP-2 (*S*-dipalmitoylglycerol CGNDESNISFKEK) derived from *Mycoplasma fermentans* was first identified and characterized by Mühlradt's group as a compound that can activate macrophages even at picomolar concentrations (24). FSL-1 (*S*-dipalmitoylglycerol

CGDPKHPKSF) derived from *Mycoplasma salivarium* has recently been characterized by our group as a potent immunostimulatory compound, whose activity has been proposed to be stronger than that of MALP-2 (16, 17, 27). MPPL-1 could induce production of IL-8 in a dose-dependent manner at a concentration of ≥ 10 nM, whereas FSL-1 and MALP-2 could induce the production of IL-8 at picomolar concentrations (Fig. 2A). To induce a level of IL-8 production similar to the level induced by 1 nM FSL-1, a 300-fold-higher concentration of MPPL-1 was required (Fig. 2A). Moreover, similar weak activity of MPPL-1 was also observed when IL-6 production in THP-1 cells was examined (Fig. 2B). In this case, the concentration of FSL-1 needed to induce a level of IL-6 production similar to that induced by 1 μ M MPPL-1 was 700-fold lower (Fig. 2B). Thus, the immunostimulatory activity of MPPL-1 is much weaker than the activities of structurally similar lipopeptides.

TLR recognition of MPPL-1. It has been shown that FSL-1 and MALP-2 stimulate human cells via recognition by TLR2 and TLR6 (26, 27, 35). We first examined whether MPPL-1 was recognized by TLR2 using HEK293 cells intrinsically lacking expression of TLR2 and responsiveness to TLR2 ligands (1). MPPL-1 could not stimulate parental HEK293 cells at concentrations ranging from 100 fM to ~ 10 μ M (data not shown) but could stimulate the cells stably transfected with TLR2, leading to induction of NF- κ B activation, in a dose-dependent manner (Fig. 3A). Therefore, MPPL-1 recognition was completely dependent on TLR2 in the same way that FSL-1 and MALP-2 recognition was. However, an approximately 1,000-fold-higher concentration of MPPL-1 was re-




FIG. 2. Cytokine-inducing activity of MPPL-1. A total of 1×10^5 THP-1 cells were stimulated for 12 h with the concentrations of MPPL-1, FSL-1, and MALP-2 indicated. Then the amounts of IL-8 (A) and IL-6 (B) released into the media were determined by ELISA. The results are representative of three separate experiments, and the data are means and standard deviations.

quired for activity similar to that of FSL-1 in TLR2-expressing HEK293 cells (Fig. 3A).

We further investigated the requirement for TLR1, TLR6, and TLR10 for recognition of MPPL-1, since TLR2 has been shown to form not only a homomer but also heteromers with these TLRs (29). MPPL-1 could not activate HEK293 cells transfected with TLR1, TLR6, or TLR10 alone (Fig. 3B). Similarly, MPPL-1 could not activate cells transfected with a combination of TLR1 and TLR6, TLR1 and TLR10, or TLR6 and TLR10 (Fig. 3B). Compared with the MPPL-1 activity in the cells transfected with TLR2 alone, cotransfection of TLR6 with TLR2 synergistically augmented the activity of MPPL-1 in a way similar to way observed with FSL-1, whereas cotransfection of TLR1 or TLR10 with TLR2 did not (Fig. 3B). Thus, MPPL-1 is preferentially recognized by TLR2/TLR6 in human cells in a manner similar to the recognition of FSL-1 and MALP-2.

Possibility of an antagonistic effect of MPPL-1 on TLR2 recognition. TLR4 recognition of *E. coli* lipopolysaccharide can be antagonized by structurally similar compounds that have weak TLR4-stimulating activities (9, 10, 23, 25). However, it is still not clear whether TLR2 recognition of lipopeptides can be antagonized by structurally similar compounds. The results described above raise the possibility that MPPL-1 has an antagonistic effect on FSL-1 recognition by TLR2/TLR6, because MPPL-1 exhibits a much lower level of activity than FSL-1 exhibits through recognition by TLR2/TLR6. We therefore examined the IL-6-producing activity of FSL-1 in the presence and absence of a higher concentration of MPPL-1.




FIG. 3. TLR usage of MPPL-1. (A) HEK293 cells stably transfected with TLR2 were prepared and transiently transfected with an NF- κ B-driven firefly luciferase reporter plasmid. The cells were stimulated for 6 h with the concentrations of MPPL-1 and FSL-1 indicated. Then the cells were lysed, and the luciferase activity was measured. The results, expressed as the means of values for triplicate wells, are representative of three separate experiments. (B) HEK293 cells were transiently transfected with an NF- κ B-driven firefly luciferase reporter plasmid together with the TLR-encoding plasmids indicated. The cells were stimulated for 6 h with 1 μ M MPPL-1 or 10 nM FSL-1. Then the cells were lysed, and the luciferase activity was measured. The results, expressed as means and standard deviations of values for triplicate wells, are representative of three separate experiments. An asterisk indicates that the *P* value was <0.05 for a comparison with the control group.

IL-6 production induced by 1 or 10 nM FSL-1 was not altered by the presence of 1 μ M MPPL-1 (Fig. 4A). Moreover, the presence of MPPL-1 was found to slightly increase the activity of FSL-1 as determined by analysis of NF- κ B activation in HEK293 cells (Fig. 4B), and this analysis was more sensitive than an IL-6 ELISA with THP-1 cells. In addition, the MPPL-1 effect on FSL-1 recognition was not altered in the presence or absence of TLR1, TLR6, or TLR10 cotransfection (Fig. 4B). Similar results were obtained in experiments using MALP-2 (data not shown).

DISCUSSION

We have been interested in the immunostimulatory activity of mycoplasma diacylated lipoproteins/lipopeptides and the pathological roles of these proteins in mycoplasma infections. So far, lipopeptides FSL-1 and MALP-2 have been identified as potent immunostimulatory compounds (22, 24). In this study, we synthesized lipopeptide MPPL-1 having a structure common in mycoplasma lipopeptides, an *S*-dipalmitoylglyceryl cysteine residue coupled to a distinct peptide, which was determined on the basis of paralogous lipoproteins charac-




FIG. 4. Antagonistic effect of MPPL-1. (A) A total of 1×10^5 THP-1 cells were stimulated for 12 h with 1 or 10 nM FSL-1 in the presence or absence of $1 \mu\text{M}$ MPPL-1. Then the amounts of IL-6 released into the media were determined by ELISA. The results, expressed as means and standard deviations, are representative of three separate experiments. (B) HEK293 cells were transiently transfected with an NF- κ B-driven firefly luciferase reporter plasmid together with the TLR-encoding plasmids indicated. The cells were stimulated for 6 h with 1 nM FSL-1 in the presence or absence of 100 nM MPPL-1. Then the cells were lysed, and the luciferase activity was measured. The results, expressed as means and standard deviations of values for triplicate wells, are representative of three separate experiments.

teristic of *M. pneumoniae*. The cytokine-inducing activity of MPPL-1 in human cells was very weak compared with that of FSL-1 or MALP-2. At a higher concentration, MPPL-1 could weakly stimulate cells via TLR2/TLR6 recognition. However, MPPL-1 could not antagonize FSL-1 recognition by TLR2. These findings raised several important possibilities for biological activities of mycoplasma lipopeptides, as discussed below.

Recent studies have revealed that the immunostimulatory activity of bacterial lipoproteins is completely dependent on the recognition and signal transduction by TLR2 that functions together with several associated molecules. TLR6 has been considered to be an essential participant in the discrimination of mycoplasma diacylated lipoproteins/lipopeptides by TLR2, because MALP-2 recognition was impaired in macrophages from TLR6-deficient mice (36) and was reduced by a blocking antibody to TLR6 in human cells (26). However, Buwitt-Beckmann et al. found that C-terminal addition of SKKKK to the peptide moiety of MALP-2 converted the MALP-2 recognition by TLR2/TLR6 into recognition by a TLR6-independent mechanism (6). In addition, we previously reported that substitution of the C-terminal amino acid of FSL-1 (F to R) greatly impaired the immunostimulatory activity (27). Therefore, discrimination of diacylated lipopeptides by TLR2 and TLR6 has been suggested to be dependent on the amino acid sequence or structure of the peptide portion, although recognition of the lipolyated cysteine residue may be dependent on other molecules, such as CD36 (15). Furthermore, a recent report suggested that TLR1 participates in the recognition of a dipalmitoylated lipoprotein derived from *M. pneumoniae* (MPN602) (33). In this study, MPPL-1 was shown to be recognized by TLR2 and TLR6 but not by TLR1 or TLR10, as observed for MALP-2 and FSL-1. We could not discern a role for TLR10 in the recognition of mycoplasma lipopeptides, although it is possible that TLR10 participates in accurate

discrimination of bacterial lipoproteins/lipopeptides in human cells.

It is possible that studies of TLR antagonists may lead to the development of efficient therapeutic regulators of microbial infection or excess inflammation. In this study, however, MPPL-1 could not antagonize TLR2 recognition of FSL-1 (Fig. 4). The weak TLR2-stimulating activity of MPPL-1 raises the possibility that the peptide moiety of MPPL-1 has a low affinity for TLR6 but does not have an affinity for either TLR1 or TLR10. This possibility may be supported by our results showing that a small amount of FSL-1, which may have a stronger affinity than MPPL-1 has, could be preferentially recognized by TLR2 and TLR6 more than a larger amount of MPPL-1 could be recognized (Fig. 4). Moreover, our results may provide strong evidence for different ligand recognition mechanisms of TLR2 and TLR4, because TLR4 recognition of lipopolysaccharide is known to be antagonized by structurally similar compounds that have weak TLR4-stimulating activities (9, 10, 23, 25). Further study is needed to determine the detailed recognition machinery of mycoplasma lipoproteins/lipopeptides.

The magnitude of the immunostimulatory activity of bacterial lipoproteins has been thought to be one of the crucial factors for pathogenicity of bacteria (3) which may be involved in the severity of host immune responses after bacterial infection. However, the presence of immunostimulatory compounds on the surface of bacterial cells leads to efficient clearance of bacteria through activation of immune cells, resulting in great reductions in efficient propagation and colonization on the host cell surface. To avoid activation of immune responses, several pathogenic bacteria have been shown to modify their surface molecules so they do not stimulate the TLR recognition system. For example, α - and ϵ -*Proteobacteria*, including *Campylobacter jejuni*, *Helicobacter pylori*, and *Bartonella bacilliformis*, modify the N-terminal D1 domain of flagellin, leading to evasion of TLR5 recognition (2). Therefore, structural modification of pathogen-activated molecular patterns may be important for bacterial pathogenicity. However, it has not been determined whether *M. pneumoniae* has the ability to evade immune systems. So far, mycoplasma lipoproteins/lipopeptides have been identified to determine strong activators of immune cells in crude mixtures of lipoproteins obtained using methods such as Triton X-114 phase separation (24, 32, 33). In a recent study performed by Shimizu et al. (33), lipoprotein MPN602, which may have the strongest activities in *M. pneumoniae* lipoprotein mixtures, was identified by using a method to separate the fraction that strongly stimulates 293T cells transfected with TLR2 to activate NF- κ B (33). MPN602 does not belong to a paralogous lipoprotein family, as shown in Table S1 in the supplemental material. Interestingly, it was also found that only a few lipoproteins possessed strong immunostimulatory activities and that the majority of lipoproteins had weak or no immunostimulatory activity (24, 32, 33). Consistent with this possibility, only a few lipoproteins with potent immunostimulatory activity have been identified so far, although there are many lipoproteins in mycoplasma species. These observations suggest that the majority of lipoproteins of *M. pneumoniae*, including paralogous lipoprotein family members, have weak immunostimulatory activities. Moreover, our results suggest that propagation of genes encoding lipoproteins with

weak immunostimulatory activity may be an important factor for the pathogenicity of *M. pneumoniae* through which the microorganism may evade TLR2 recognition. Further detailed investigations of the functions and immunostimulatory activities of lipoproteins found in *M. pneumoniae* are needed to address this possibility.

The bacterial lipoprotein structure has been found to be a lipidated (commonly palmitoylated) triacylated or diacylated *S*-glyceryl cysteine residue coupled to distinct polypeptides. However, the coupled peptide sequence has been shown to have a great effect on the immunostimulatory activity of the whole molecule. Therefore, synthesis and characterization of lipopeptides based on the known lipoprotein sequences of the N terminus may be an effective method for determining unknown biological activities of bacterial lipoproteins. Moreover, exhaustive screening of synthetic lipopeptides can lead to the identification of novel bacterial pathogenicities and to the development of biologically beneficial compounds or immune regulators. Also, it is possible that a cognate ligand for TLR10 will be identified by screening of these lipopeptides.

ACKNOWLEDGMENTS

This work was supported by grants-in-aid for young scientists (B): 16791102 and (B):18791363 to T.I. provided by the Ministry of Education, Culture, Sports, Science and Technology, Japan.

REFERENCES

- Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. *Science* 285:736-739.
- Andersen-Nissen, E., K. D. Smith, K. L. Strobe, S. L. Barrett, B. T. Cookson, S. M. Logan, and A. Aderem. 2005. Evasion of Toll-like receptor 5 by flagellated bacteria. *Proc. Natl. Acad. Sci. USA* 102:9247-9252.
- Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. B. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, P. J. Brennan, B. R. Bloom, P. J. Godowski, and R. L. Modlin. 1999. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. *Science* 285:732-736.
- Bulut, Y., E. Faure, L. Thomas, O. Equils, and M. Arditi. 2001. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and *Borrelia burgdorferi* outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. *J. Immunol.* 167:987-994.
- Buwitt-Beckmann, U., H. Heine, K. H. Wiesmuller, G. Jung, R. Brock, S. Akira, and A. J. Ulmer. 2006. TLR1- and TLR6-independent recognition of bacterial lipopeptides. *J. Biol. Chem.* 281:9049-9057.
- Buwitt-Beckmann, U., H. Heine, K. H. Wiesmuller, G. Jung, R. Brock, S. Akira, and A. J. Ulmer. 2005. Toll-like receptor 6-independent signaling by diacylated lipopeptides. *Eur. J. Immunol.* 35:282-289.
- Chambaud, L., H. Wroblewski, and A. Blanchard. 1999. Interactions between mycoplasma lipoproteins and the host immune system. *Trends Microbiol.* 7:493-499.
- Chuang, T., and R. J. Ulevitch. 2001. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. *Biochim. Biophys. Acta* 1518:157-161.
- Coats, S. R., T. T. Pham, B. W. Bainbridge, R. A. Reife, and R. P. Darveau. 2005. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize *Escherichia coli* lipopolysaccharide at the TLR4 signaling complex. *J. Immunol.* 175:4490-4498.
- Coats, S. R., R. A. Reife, B. W. Bainbridge, T. T. Pham, and R. P. Darveau. 2003. *Porphyromonas gingivalis* lipopolysaccharide antagonizes *Escherichia coli* lipopolysaccharide at Toll-like receptor 4 in human endothelial cells. *Infect. Immun.* 71:6799-6807.
- Hallama, K. M., G. F. Browning, and S. L. Tang. 2006. Lipoprotein multigene families in *Mycoplasma pneumoniae*. *J. Bacteriol.* 188:5393-5399.
- Hasan, U., C. Chaffois, C. Gaillard, V. Saulnier, E. Merck, S. Tancredi, C. Guet, F. Briere, J. Vlach, S. Lebecque, F. Tricchi, and E. E. Bates. 2005. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. *J. Immunol.* 174:2942-2950.
- Himmelreich, R., H. Hilbert, H. Plagens, E. Pirk, B. C. Li, and R. Herrmann. 1996. Complete sequence analysis of the genome of the bacterium *Mycoplasma pneumoniae*. *Nucleic Acids Res.* 24:4420-4449.
- Himmelreich, R., H. Plagens, H. Hilbert, B. Reiner, and R. Herrmann. 1997. Comparative analysis of the genomes of the bacteria *Mycoplasma pneumoniae* and *Mycoplasma genitalium*. *Nucleic Acids Res.* 25:701-712.
- Hoeb, K., P. Georgel, S. Rutschmann, X. Du, S. Mudd, K. Crozat, S. Sovath, L. Shamel, T. Hartung, U. Zahring, and B. Beutler. 2005. CD36 is a sensor of diacylglycerides. *Nature* 433:523-527.
- Hubschle, T., J. Mutze, P. F. Muhradt, S. Korte, R. Gerstberger, and J. Roth. 2006. Pyrexia, anorexia, adiposa, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 290:R180-187.
- Into, T., M. Fujita, T. Okusawa, A. Hasebe, M. Morita, and K. Shibata. 2002. Synergic effects of mycoplasma lipopeptides and extracellular ATP on activation of macrophages. *Infect. Immun.* 70:3586-3591.
- Into, T., K. Kiura, M. Yasuda, H. Kataoka, N. Inoue, A. Hasebe, K. Takeda, S. Akira, and K. Shibata. 2004. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipopeptides of *Mycoplasma fermentans* induces apoptotic cell death after NF- κ B activation. *Cell. Microbiol.* 6:187-199.
- Into, T., Y. Nodasaka, A. Hasebe, T. Okuzawa, J. Nakamura, N. Ohata, and K. Shibata. 2002. Mycoplasma lipopeptides induce Toll-like receptor 2- and caspase-mediated cell death in lymphocytes and monocytes. *Microbiol. Immunol.* 46:265-276.
- Into, T., and K. Shibata. 2005. Apoptosis signal-regulating kinase 1-mediated sustained p38 mitogen-activated protein kinase activation regulates mycoplasma lipoprotein- and staphylococcal peptidoglycan-triggered Toll-like receptor 2 signalling pathways. *Cell. Microbiol.* 7:1305-1317.
- Kirschning, C. J., and R. R. Schumann. 2002. TLR2: cellular sensor for microbial and endogenous molecular patterns. *Curr. Top. Microbiol. Immunol.* 270:121-144.
- Kiura, K., H. Kataoka, T. Nakata, T. Into, M. Yasuda, S. Akira, N. Inoue, and K. Shibata. 2006. The synthetic analogue of mycoplasma lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2. *FEMS Immunol. Med. Microbiol.* 46:78-84.
- Lepper, P. M., M. Triantafyllou, C. Schumann, E. M. Schneider, and K. Triantafyllou. 2005. Lipopolysaccharides from *Helicobacter pylori* can act as antagonists for Toll-like receptor 4. *Cell. Microbiol.* 7:519-528.
- Muhradt, P. F., M. Kiess, H. Meyer, R. Sussmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from *Mycoplasma fermentans* acting at picomolar concentration. *J. Exp. Med.* 185:1951-1958.
- Mullarkey, M., J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, and D. P. Rossignol. 2003. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. *J. Pharmacol. Exp. Ther.* 304:1093-1102.
- Nakao, Y., K. Funami, S. Kikkawa, M. Taniguchi, M. Nishiguchi, Y. Fukumori, T. Seya, and M. Matsumoto. 2005. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. *J. Immunol.* 174:1566-1573.
- Okusawa, T., M. Fujita, J. Nakamura, T. Into, M. Yasuda, A. Yoshimura, Y. Hara, A. Hasebe, D. T. Golenbock, M. Morita, Y. Kuroki, T. Ogawa, and K. Shibata. 2004. Relationship between structures and biological activities of mycoplasma diacylated lipopeptides and their recognition by Toll-like receptors 2 and 6. *Infect. Immun.* 72:1657-1665.
- Omuetti, K. O., J. M. Beyer, C. M. Johanson, E. A. Lyle, and R. I. Tapping. 2005. Domain exchange between human Toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. *J. Biol. Chem.* 280:36616-36625.
- Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. *Proc. Natl. Acad. Sci. USA* 97:13766-13771.
- Rawadi, G. 2000. *Mycoplasma fermentans* interaction with monocytes/macrophages: molecular basis. *Microbes Infect.* 2:955-964.
- Rottem, S. 2003. Interaction of mycoplasmas with host cells. *Physiol. Rev.* 83:417-432.
- Shibata, K., A. Hasebe, T. Into, M. Yamada, and T. Watanabe. 2000. The N-terminal lipopeptide of a 44-kDa membrane-bound lipoprotein of *Mycoplasma salivarium* is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. *J. Immunol.* 165:6538-6544.
- Shimizu, T., Y. Kida, and K. Kuwano. 2005. A dipalmitoylated lipoprotein from *Mycoplasma pneumoniae* activates NF- κ B through TLR1, TLR2, and TLR6. *J. Immunol.* 175:4641-4646.
- Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. *Annu. Rev. Immunol.* 21:335-376.
- Takeuchi, O., A. Kaufmann, K. Grote, T. Kawai, K. Hoshino, M. Morr, P. F. Muhradt, and S. Akira. 2000. Preferentially the R-stereoisomer of the mycoplasma lipopeptide macrophage-activating lipopeptide-2 activates im-

- mune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. *J. Immunol.* 164:554-557.
36. Takeuchi, O., T. Kawai, P. F. Muhlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. *Int. Immunol.* 13:933-940.
37. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. *J. Immunol.* 169:10-14.
38. Waites, K. B., and D. F. Talkington. 2004. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin. Microbiol. Rev.* 17:697-728.
39. Weiner, J., 3rd, R. Herrmann, and G. F. Browning. 2000. Transcription in *Mycoplasma pneumoniae*. *Nucleic Acids Res.* 28:4488-4496.

Editor: D. L. Burns

Pathogen Recognition by Toll-like Receptor 2 Activates Weibel-Palade Body Exocytosis in Human Aortic Endothelial Cells*

Received for publication, October 24, 2006, and in revised form, December 22, 2006. Published, JBC Papers in Press, January 16, 2007, DOI 10.1074/jbc.M609962200

Takeshi Into^{†1}, Yosuke Kanno[‡], Jun-ichi Dohkan[‡], Misako Nakashima[‡], Megumi Inomata[‡], Ken-ichiro Shibata[‡], Charles J. Lowenstein[§], and Kenji Matsushita[‡]

From the [†]Department of Oral Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morioka, Obu, Aichi 474-8522, Japan, the [‡]Laboratory of Oral Molecular Microbiology, Department of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine, Sapporo 060-8586, Japan, and the [§]Departments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

The endothelial cell-specific granule Weibel-Palade body releases vasoactive substances capable of modulating vascular inflammation. Although innate recognition of pathogens by Toll-like receptors (TLRs) is thought to play a crucial role in promotion of inflammatory responses, the molecular basis for early-phase responses of endothelial cells to bacterial pathogens has not fully been understood. We here report that human aortic endothelial cells respond to bacterial lipoteichoic acid (LTA) and synthetic bacterial lipopeptides, but not lipopolysaccharide or peptidoglycan, to induce Weibel-Palade body exocytosis, accompanied by release or externalization of the storage components von Willebrand factor and P-selectin. LTA could activate rapid Weibel-Palade body exocytosis through a TLR2- and MyD88-dependent mechanism without *de novo* protein synthesis. This process was at least mediated through MyD88-dependent phosphorylation and activation of phospholipase C γ . Moreover, LTA activated interleukin-1 receptor-associated kinase-1-dependent delayed exocytosis with *de novo* protein synthesis and phospholipase C γ -dependent activation of the NF- κ B pathway. Increased TLR2 expression by transfection or interferon- γ treatment increased TLR2-mediated Weibel-Palade body exocytosis, whereas reduced TLR2 expression under laminar flow decreased the response. Thus, we propose a novel role for TLR2 in induction of a primary proinflammatory event in aortic endothelial cells through Weibel-Palade body exocytosis, which may be an important step for linking innate recognition of bacterial pathogens to vascular inflammation.

atherosclerosis. Early endothelial activation involves dual phases: rapid translocation of P-selectin to the endothelial surface and slower synthesis and expression of adhesion molecules such as ICAM-1 (intercellular adhesion molecule 1).² The former process is accompanied by rapid exocytosis of Weibel-Palade bodies, which are endothelial cell-specific storage granules that contain vascular modulators, including von Willebrand factor (VWF), P-selectin, IL-8, eotaxin-3, endothelin-1, CD63/lamp3, osteopontin, and angiopoietin-2 (1, 2). During Weibel-Palade body exocytosis, these proteins are transported to the outside of the cell upon stimulation or vascular damage and may control local or systemic pathobiological effects, including thrombosis and atherogenesis. Regulated Weibel-Palade body exocytosis is known to be initiated through an increase of intracellular calcium level after stimulation with various secretagogues, including calcium ionophores, thrombin, histamine, TNF- α , and extracellular ATP (1, 2).

Recently, excess innate immune responses of vessel walls or endothelium to invading pathogens have been suggested to be linked to atherogenesis. Several common bacterial infectious agents or invasive pathogens, such as *Chlamydia pneumoniae*, *Helicobacter pylori*, *Porphyromonas gingivalis*, and oral commensal bacteria, have so far been detected in vessel walls or atherosclerotic lesions in humans (3, 4). However, the linkage between artery endothelial innate recognition of such pathogens and inflammatory responses has not been fully elucidated.

For the detection of invasive bacteria in host defense, several Toll-like receptors (TLRs) are employed to identify molecular motifs that usually compose bacterial bodies (5). Among TLR members in humans, TLR2 detects the widest range of common bacterial constituents, such as lipoteichoic acids (LTA),

² The abbreviations used are: ICAM-1, intercellular adhesion molecule 1; BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid-acetoxymethyl ester; FSL-1, synthetic 5-dipalmitoylglycerol-CGDPKHPKSF derived from *Mycoplasma salivarium*; HAEC, human aortic endothelial cell; HUVEC, human umbilical vein endothelial cell; IRAK, IL-1R-associated kinase; LTA, lipoteichoic acid; MALP-2, synthetic 5-dipalmitoylglycerol-CGNDESINISFKEK derived from *Mycoplasma fermentans*; Pam₂CSK₆, synthetic *N*-palmitoyl-5-dipalmitoylglycerol-CSK₆ derived from *E. coli*; PGN, peptidoglycan; PLC, phospholipase C; TLR, Toll-like receptor; TNF, tumor necrosis factor; TNFR, TNF receptor; TRAF, TNFR-associated factor; VWF, von Willebrand factor; LPS, lipopolysaccharide; IL-1R, interleukin-1 receptor; siRNA, small interference RNA; ELISA, enzyme-linked immunosorbent assay; PI3K, phosphatidylinositol 3-kinase; IFN, interferon.

The onset of inflammatory responses of vascular endothelial cells plays crucial roles in recruitment of immune cells, thrombus formation, and development of vascular inflammation or

* This work was supported by a Grant-in-aid for Young Scientists (B) (18791363 to T. I.) provided by the Ministry of Education, Culture, Sports, Science and Technology and by Mitsui Life Social Welfare Foundation, Aichi Cancer Research Foundation, Mitsubishi Pharma Research Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, and Suzuken Memorial Foundation (to K. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[†] To whom correspondence should be addressed. Tel.: 81-562-44-5651; Fax: 81-562-46-8684; E-mail: into@nsls.go.jp.

peptidoglycans (PGN), bacterial di- or triacylated lipoproteins or lipopeptides, lipoarabinomannans, porins, and fimbriae (5–8). TLR4 and TLR5 contribute to the recognition of only a few bacterial components, *i.e.* LPS and flagellin (9, 10). Because TLR1 and TLR6 participate in the accurate discrimination of molecular structures by TLR2 as coreceptors, several molecules, including CD14, CD36, and LOX-1, further facilitate the interactions of TLR2 with bacterial pathogens (5, 11, 12). After recognition of cognate agonists, endothelial TLRs activate the classic Toll/IL-1R signaling pathway utilizing MyD88 and IL-1R-associated kinase (IRAK)-1, which ultimately activate a TNFR-associated factor (TRAF) 6 complex and I κ Bs and the release and translocation of active NF- κ B to the nucleus. The artery endothelial NF- κ B signaling pathways downstream of TLRs are thought to participate in the development of artery inflammatory diseases or atherogenesis through the promotion of the expression of a large number of proinflammatory mediators and adhesion molecules (13–15). However, it is still not known whether artery endothelial TLRs are primary initiators or modulators of the diseases.

In this study, we investigated the early-phase proinflammatory responses of human aortic endothelial cells (HAECs) to bacterial cell wall constituents. We found that recognition of bacterial constituents by TLRs, especially by TLR2 but not TLR4, could activate Weibel-Palade body exocytosis. We further investigated the involvement of MyD88 in regulation of the cell response.

EXPERIMENTAL PROCEDURES

Reagents, Chemicals, and Antibodies—LTA and PGN from *Staphylococcus aureus* and LPS from *Escherichia coli* O26:B6 were obtained from Sigma-Aldrich. Rough-form LPS from *Salmonella minnesota* R595 and flagellin from *Salmonella typhimurium* strain 14028 were obtained from Alexis Biochemicals. Pam₃CSK₄ (16) was obtained from InvivoGen. Preparation of FSL-1 and MALP-2 was described previously (17–19). A23187, the cell-permeable calcium chelator 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid-acetoxymethyl ester (BAPTA-AM), cycloheximide, and the phospholipase C (PLC) γ inhibitor U-73122 were purchased from Sigma. LY294002 was purchased from Calbiochem. Monoclonal antibodies to human TLR2, TLR2.1 (BD Biosciences), TLR2.3 (eBioscience), and IMG-319 (Immugenex), were purchased for a TLR2 blocking study and flow cytometry. Antibodies to PLC γ 1 and phosphorylated PLC γ 1 (Y783) were obtained from Cell Signaling Biotechnology. All other reagents were obtained from Sigma-Aldrich unless otherwise indicated.

DNA Cloning—A human TLR2-encoding plasmid was prepared as described previously (17). The dominant negative TLR2 (P681H) was constructed using a QuikChange II site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions.

Cell Culture and Transfection of siRNA—HEK293 cells and human monocytic THP-1 cells were grown as described previously (20). HAECs and HUVECs were grown in endothelial growth medium-2 (Cambrex) as described previously (21). These endothelial cells were used for experiments from passages 4 to 8. All of the gene-specific siRNA oligonucleotides for

human TLR1, TLR2, TLR6, MyD88, and IRAK-1 and a control oligonucleotide were purchased from Dharmacon. Although the sequences were not provided by the manufacturer, significant suppressive effects on the respective gene expression could be confirmed by reverse transcription-PCR compared with the control transfection (data not shown). For the transfection of siRNA, confluent HAECs or HUVECs seeded on 6- or 24-well plates were prepared and washed once with Opti-MEM 1 medium (Invitrogen). Transfection of siRNAs (100 nM) was performed with Lipofectin reagent (Invitrogen) as instructed by the manufacturer. Toxi-Blocker transfection supplement (TOYOBO) was used to prevent cytotoxicity of lipofection reagents. After 12 h of incubation, culture media were changed to endothelial growth medium-2 media, and incubation was continued for 24 h.

Luciferase Reporter Gene Assay—HEK293 cells stably transfected with human TLR2 gene (or mock control vector) were plated at 5×10^4 cells/well in 24-well plates before DNA transfection. The cells were transiently transfected with 50 ng of an NF- κ B-driven firefly luciferase reporter plasmid (pNF- κ B-Luc, Stratagene) and 5 ng of a construct directing expression of *Renilla* luciferase under the control of a constitutively active thymidine kinase promoter (pRL-TK, Promega). After 12 h of incubation, the cells were transfected with 100 nM siRNA oligonucleotide for MyD88 (or glyceraldehyde-3-phosphate dehydrogenase control). Toxi-Blocker transfection supplement was used to prevent cytotoxicity of lipofection reagents. After a further 24 h of incubation, the cells were stimulated with TLR2 agonists in media containing 1% fetal bovine serum for 6 h. Then the cells were lysed, and luciferase activity was measured as described previously (17, 20).

Determination of VWF, IL-8, and TNF- α by ELISA—HAECs were grown on 24-well plates, then washed and placed in 200 μ l of Opti-Mem 1 (Invitrogen) containing 1% fetal bovine serum without growth factors, and stimulated with various concentrations of TLR2 agonists for 60 min. The amount of VWF released into the medium was measured by a VWF ELISA kit (American Diagnostica) according to the manufacturer's instructions. Results are representative of three separate experiments and expressed as means \pm S.D. To clarify the mechanism by which TLR2 induces VWF exocytosis, HAECs were pretreated for 30 min with 10 μ M U-73211 and then stimulated with LTA for 60 min. For other experiments, HAECs were pretreated with 10 μ M BAPTA-AM for 30 min or 10 ng/ml IFN- γ for 12 h or precultured with CaCl₂-free DMEM for 1 h. To determine the amounts of IL-8 released, HAECs were grown on 96-well plates and then washed and placed in 200 μ l of Opti-Mem 1 (Invitrogen) containing 1% fetal bovine serum and stimulated for 4 h with various concentrations of TLR2 agonists. The amounts of IL-8 released into the media were measured by human IL-8 Cytoset (Invitrogen) according to the manufacturer's instructions. THP-1 cells (1×10^5) were stimulated for 6 h with various concentrations of TLR2 agonists. The amounts of TNF- α released into the media were measured by human TNF- α Cytoset (Invitrogen) according to the manufacturer's instructions. Results are representative of three separate experiments and expressed as means \pm S.D.

TLR2 Mediates Weibel-Palade Body Exocytosis

Adhesion Assay—Confluent HAECs seeded on 24-well plates were treated with 10 $\mu\text{g/ml}$ LTA for 60 min. The culture medium was then removed, and monocytic THP-1 cells (2.5×10^5) prelabeled with Alexa564-conjugated concanavalin A were added to the culture. Cells were then allowed to adhere for 30 min on a rocking platform. After two washes with phosphate-buffered saline, fluorescent images were immediately obtained by a fluorescent microscope IX71 with DP70 image capture (Olympus) and processed using Adobe Photoshop, version 7.0. Adhesion of red fluorescent cells was quantified in three fields per well. Results are representative of three separate experiments and expressed as means \pm S.D.

Immunofluorescence of VWF—Confluent HAECs were treated with 10 $\mu\text{g/ml}$ LTA or 10 μM A23187 for 60 min. The culture media were removed, and the cells were immediately fixed at -20°C with methanol for 60 min. Immunostaining was carried out using an anti-VWF rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and Alexa488-conjugated secondary antibody (Invitrogen). Cell nuclei were also stained with 2.5 $\mu\text{g/ml}$ Hoechst 33342 for 30 min. Images were obtained by a fluorescent microscope IX71 (magnification: $\times 40$) with DP70 image capture (Olympus) in the presence of the Prolong Gold Antifade reagent (Invitrogen) and processed using Adobe Photoshop, version 7.0 (Adobe). Results are representative of three separate experiments.

Immunoblot Analysis—Confluent HAECs seeded on 60-mm plates were transfected with gene-specific siRNA and incubated in Opti-Mem I media containing 5% fetal bovine serum for 4–6 h. The cells were stimulated with 1 $\mu\text{g/ml}$ LTA for 0–60 min and lysed with a buffer consisting of 20 mM Tris-hydrochloride (pH 7.2), 150 mM sodium chloride, 5 mM EDTA, and 1% Triton X-100 in the presence of protease inhibitors (Roche Applied Science) at 4°C for 15 min followed by clarification by centrifugation at $12,000 \times g$ for 10 min. SDS-PAGE and immunoblot analyses were performed as described previously (17, 20). Results are representative of three separate experiments.

Flow Cytometry—To assess the surface expression of P-selectin, confluent HAECs were treated with 10 $\mu\text{g/ml}$ LTA for 30 min. To assess the surface expression of TLR2, confluent HAECs or HUVECs were treated with 10 ng/ml IFN- γ or they were incubated for 12 h under laminar flow. Cell culture under laminar flow was performed with a cone and plate apparatus as described previously (22). Magnitude of the flow was controlled at $\sim 15 \text{ dyn/cm}^2$. The cells were then removed with phosphate-buffered saline containing 20 mM EDTA and fixed with phosphate-buffered saline containing 4% paraformaldehyde at 4°C for 60 min. The cells were then incubated at 4°C for 60 min with anti-TLR2 monoclonal antibody (IMG-319), anti-P-selectin monoclonal antibody (BD Biosciences), or isotype-matched mouse IgG and then with fluorescein isothiocyanate-conjugated anti-mouse IgG. Fluorescence was measured using a FACSCalibur (BD Biosciences).

Statistics—All values were evaluated by statistical analysis using one-way analysis of variance and Student-Newman-Keul's test. Differences were considered to be statistically significant at the level of $p < 0.05$.




FIGURE 1. MyD88-dependent Weibel-Palade body exocytosis by bacterial constituents. *A*, HAECs stimulated with 10 $\mu\text{g/ml}$ LTA or 1 μM A23187 for 60 min were fixed and stained immunofluorescently with anti-VWF antibody (green) and with Hoechst33342 (blue). *Left*, unstimulated; *middle*, stimulated with LTA; *right*, stimulated with A23187. *B*, HAECs were stimulated with 1 $\mu\text{g/ml}$ LTA or 1 μM A23187 for the indicated periods. The amounts of VWF released into the media were measured by ELISA. Each value is the mean \pm S.D. ($n = 3$). *C*, HAECs transfected with MyD88 or IRAK1-specific or control siRNA were prepared. Cells were pretreated with 10 $\mu\text{g/ml}$ cycloheximide for 30 min and then washed and stimulated with 10 $\mu\text{g/ml}$ LTA for 60 min or 4 h. The amounts of VWF released into the media were measured by ELISA. Each value is the mean \pm S.D. ($n = 3$). *versus* control group, $p < 0.01$. *D*, HAECs transfected with MyD88-specific or control siRNA were stimulated with *E. coli* LPS O26:B6 (0.01–1 $\mu\text{g/ml}$), LPS from *S. minnesota* (0.01–1 $\mu\text{g/ml}$), flagellin from *S. typhimurium* (0.1–10 $\mu\text{g/ml}$), LTA from *S. aureus* (0.1–10 $\mu\text{g/ml}$), PGN from *S. aureus* (0.1–10 $\mu\text{g/ml}$), Pam₂CSK₄ (0.1–10 $\mu\text{g/ml}$), FSL-1 (0.01–1 $\mu\text{g/ml}$), MALP-2 (0.01–1 $\mu\text{g/ml}$), and A23187 (0.1–10 μM) for 60 min, and then the amounts of VWF released into the media were measured. Each value is the mean \pm S.D. ($n = 3$).

RESULTS

Induction of Weibel-Palade Body Exocytosis by Bacterial Constituents—We first examined whether bacterial LTA activated degranulation of Weibel-Palade bodies, because LTA has been reported to stimulate vascular endothelial cells, leading to induction of production of proinflammatory mediators, dysfunction, or cell death (23–25). After stimulation of HAECs for 30 min, LTA clearly decreased the amount of Weibel-Palade bodies, stained with an antibody to VWF, in the cells (Fig. 1A). Compared with the calcium ionophore (A23187)-induced response, we found that LTA gradually activated Weibel-Palade body exocytosis, quantification of which was performed by measuring the amount of VWF released into the media (Fig. 1B). VWF release by stimulation with

LTA for 60 min was not suppressed by treatment with the protein synthesis inhibitor cycloheximide, whereas the release by stimulation with LTA for 4 h was significantly suppressed by the treatment (Fig. 1C). We further investigated whether LTA induction of exocytosis was mediated through MyD88 and IRAK-1, common signaling molecules downstream of TLRs, because LTA is known as a TLR2 agonist. Interestingly, VWF release by stimulation with LTA for 60 min was suppressed by knockdown of the expression of MyD88 but not that of IRAK-1, whereas the release by stimulation with LTA for 4 h was significantly suppressed by each knockdown of MyD88 and IRAK-1 (Fig. 1C). Thus, these results suggest that LTA can induce Weibel-Palade body exocytosis through a MyD88-dependent rapid mechanism without *de novo* protein synthesis and an IRAK-1-dependent slower mechanism with *de novo* protein synthesis.

We also examined whether other bacterial cell wall constituents, as shown in Table 1, activated induction of VWF release after stimulation of HAECs for 60 min. Among the compounds that we tested, the synthetic analogs of bacterial lipoproteins Pam₃CSK₄, FSL-1, and MALP-2 and, to a lesser extent, flagellin induced VWF release in a dose-dependent manner (Fig. 1D, left). Interestingly, LPS from different bacterial species and PGN did not activate Weibel-Palade body exocytosis (Fig. 1D, left). In addition, we found that induction of exocytosis by bacterial compounds was also mediated by MyD88 as well as that by LTA (Fig. 1D, right). These results suggest that several types of, but not all, bacterial cell wall constituents can activate induction of TLR-MyD88-mediated exocytosis.

TABLE 1
Bacterial cell wall constituents used in this study

Substance	Origin (Ref.)	TLR recognition in human cells (Ref.)
LTA	<i>S. aureus</i>	TLR2 (7)
LPS	<i>E. coli</i>	TLR4 (10)
LPS	<i>S. minnesota</i>	TLR4 (10)
Flagellin	<i>S. typhimurium</i>	TLR5 (9)
PGN	<i>S. aureus</i>	TLR2 (8)
Pam ₃ CSK ₄	Synthesis (<i>E. coli</i>) (16)	TLR1/TLR2 (41)
FSL-1	Synthesis (<i>M. salivarium</i>) (18)	TLR2/TLR6 (17)
MALP-2	Synthesis (<i>M. fermentans</i>) (19)	TLR2/TLR6 (55)




FIGURE 2. MyD88-dependent P-selectin externalization by LTA. *A*, HAECs transfected with MyD88-specific or control siRNA were stimulated with 10 µg/ml LTA for 60 min, and then surface P-selectin was detected by flow cytometry. Shaded histogram, not stimulated; gray, stimulated with LTA. *B*, HAECs transfected with MyD88-specific or control siRNA were stimulated with 10 µg/ml LTA for 60 min, and monocytes stained with conA-Alexa594 were then allowed to adhere for 20 min. Adhesion of red fluorescent cells was quantified in three fields per well by using an image analysis system. Each value is the mean \pm S.D. ($n = 3$). $^* p < 0.01$.

Regarding the process of Weibel-Palade body exocytosis, we found that MyD88-dependent externalization of P-selectin was induced after stimulation of HAECs with LTA for 30 min (Fig. 2A). In addition, monocyte adhesion to HAECs was modestly increased in a MyD88-dependent fashion after LTA stimulation for 60 min (Fig. 2B).

Stimulatory Activities of LPS and PGN in HAECs—As stated above, LPS did not activate Weibel-Palade body exocytosis (Fig. 1D). However, LPS potently activated induction of MyD88-dependent IL-8 production in HAECs after stimulation for 4 h (Fig. 3A). Thus, the results shown in Figs. 1D and 3A suggest that endothelial TLR4 lacks the ability to induce rapid Weibel-Palade body exocytosis without *de novo* protein synthesis. Similarly to LPS, PGN did not activate Weibel-Palade body exocytosis (Fig. 1D). Also, PGN did not induce IL-8 production after stimulation for 4 h in HAECs, whereas LTA did (Fig. 3A). However, our preparation of PGN had activities to induce TNF- α production in THP-1 monocytes (Fig. 3B) and TLR2- and MyD88-dependent activation of NF- κ B in HEK293 cells (Fig. 3C) in a way similar to that in the case of other TLR2 agonists. These results suggest that HAECs lack the ability to respond to PGN.

Induction of Weibel-Palade Body Exocytosis through TLR2—We then focused on LTA- and bacterial lipopeptide-induced Weibel-Palade body exocytosis. It has been reported that LTA and bacterial lipopeptides are TLR2 agonists (Table 1). In HUVECs, the lipopeptide FSL-1 induced VWF release (Fig. 4A). We found that this response was enhanced by increased expression of TLR2 by gene transfection (Fig. 4A). This result suggests that TLR2 recognition of bacterial constituents directly activates Weibel-Palade body exocytosis. Moreover, transfection of mutated TLR2 (P681H), which lacks the ability to interact with MyD88 (26), suppressed the release (Fig. 4B), consistent with the results presented in Figs. 1D and 2A showing that MyD88 was involved in the induction of Weibel-Palade exocytosis. In HAECs, knockdown of TLR2 expression resulted in almost complete suppression of VWF release by Pam₃CSK₄, FSL-1, MALP-2, and LTA (Fig. 4B). Moreover, knockdown of TLR6 expression resulted in a decrease in the activities of LTA, FSL-1, and MALP-2 and even that of Pam₃CSK₄ (Fig. 4B). In contrast to this, TLR1 interference did not affect VWF release (Fig. 4B),

consistent with our observation that HAECs express very low levels of TLR1 mRNA compared with the levels of TLR2 mRNA (data not shown). These results suggest that endothelial recognition of pathogens by TLR2, or to a lesser extent by TLR6, contributes to induction of Weibel-Palade body exocytosis.

Involvement of PLC γ Activation in Weibel-Palade Body Exocytosis—Recent studies have shown that TLR2 signal transduction results in an increase of intracellular calcium level (27, 28). Indeed, we found that the intracellular calcium chelator BAPTA-AM suppressed LTA-induced exocytosis (Fig. 5A). We

TLR2 Mediates Weibel-Palade Body Exocytosis




FIGURE 3. Stimulatory activities of LPS and PGN in HAECs. A, HAECs transfected with MyD88-specific or control siRNA were stimulated with LTA (0.1–10 $\mu\text{g/ml}$), PGN (0.1–10 $\mu\text{g/ml}$), and LPS (1–100 ng/ml) for 4 h, and then the amounts of IL-8 released into the media were measured. Each value is the mean \pm S.D. ($n = 3$). B, THP-1 cells were stimulated with PGN (0.1–10 $\mu\text{g/ml}$), LTA (0.1–10 $\mu\text{g/ml}$), and FSL-1 (10–1 $\mu\text{g/ml}$) for 6 h, and then the amounts of TNF- α released into the media were measured. Each value is the mean \pm S.D. ($n = 3$). C, HEK293 cells stably expressing TLR2, and control cells were prepared and then transfected with MyD88-specific siRNA and NF- κ B-driven luciferase gene. The cells were stimulated with Pam₂CSK₄ (0.1–10 $\mu\text{g/ml}$), FSL-1 (0.01–1 $\mu\text{g/ml}$), MALP-2 (0.01–1 $\mu\text{g/ml}$), LTA (0.1–10 $\mu\text{g/ml}$), PGN (0.1–10 $\mu\text{g/ml}$), and LPS (1–100 ng/ml) for 6 h, and then luciferase activity was measured. Each value is the mean \pm S.D. ($n = 3$).

therefore examined the role of PLC γ , a common regulator of intracellular calcium release by generating inositol 1,4,5-triphosphate (29), during TLR2-mediated Weibel-Palade body exocytosis. We found that the PLC γ inhibitor U-73122 significantly suppressed TLR2 agonist-induced VWF release (Fig. 5B). Because PLC γ isoforms are thought to be activated by phosphatidylinositol 3,4,5-trisphosphate, the product of phosphatidylinositol 3-kinases (PI3Ks) (29), TLR2-mediated exocytosis was suppressed by the chemical inhibitor of PI3K LY294002 (data not shown). However, downstream of TLR/IL-1R, activation of PI3K is regulated through a MyD88-independent machinery (30), conflicting with our results showing that Weibel-Palade body exocytosis requires MyD88 (Figs. 1D and 2A). Because enzymatic activity of PLC γ is also regulated by tyrosine phosphorylation (31), we tested whether this event was mediated by MyD88. Phosphorylation of PLC γ 1 at the Tyr-738 residue was induced by LTA stimulation (Fig. 5C). Interestingly, this activity was efficiently suppressed by knockdown of MyD88 expression but not by knockdown of IRAK-1 expression (Fig. 5C). MyD88-dependent activation of PLC γ was also observed in TLR2-overexpressed 293 cells used as non-endothelial cells (data not shown). These results suggest that TLR2-mediated rapid Weibel-Palade body exocytosis is regulated by




FIGURE 4. Involvement of TLR2 in Weibel-Palade body exocytosis. A, HUVECs transfected with WT or P681H mutant of TLR2 or with a control plasmid were stimulated with 1 $\mu\text{g/ml}$ FSL-1 for 60 min, and then the amounts of VWF released into the media were measured. Each value is the mean \pm S.D. ($n = 3$). B, HAECs transfected with TLR1-, TLR2-, or TLR6-specific or control siRNA were stimulated with Pam₂CSK₄ (10 $\mu\text{g/ml}$), FSL-1 (1 $\mu\text{g/ml}$), MALP-2 (1 $\mu\text{g/ml}$), and LTA (10 $\mu\text{g/ml}$) for 60 min, and then the amounts of VWF released into the media were measured. Each value is the mean \pm S.D. ($n = 3$). *, $p < 0.05$.

activation of PLC γ through MyD88-dependent tyrosine phosphorylation.

We also investigated the role of PLC γ in TLR2-mediated NF- κ B signaling. U-73122 treatment clearly suppressed TLR2 agonist-induced production of the NF- κ B-driven chemokine IL-8 in HAECs (Fig. 5D). U-73122 treatment also suppressed LTA-induced phosphorylation and degradation of I κ B α in HAECs (Fig. 5E). These results suggest that the MyD88-PLC γ pathway also mediates inflammatory responses through NF- κ B activation in endothelial cells.

Regulation of TLR2-mediated Weibel-Palade Body Exocytosis—The results shown in Fig. 4 (A and B) raised the possibility that alteration of endothelial TLR2 expression affects the magnitude of Weibel-Palade body exocytosis. We examined TLR2-mediated exocytosis in the presence of vascular modulators, IFN- γ or laminar flow, which are known to affect TLR2 expression in endothelial cells of human origin. Consistent with the results of a previous study (32), treatment with IFN- γ increased TLR2 expression level in HAECs (Fig. 6A). Under this condition, the magnitude of TLR2-mediated exocytosis was significantly increased (Fig. 6B). In contrast to this, TLR2 expression slightly decreased in HAECs incubated under laminar flow (Fig. 6C), consistent with the results of a previous study (33). We found that laminar flow decreased the magnitude of TLR2-mediated exocytosis (Fig. 6D).

DISCUSSION

The major finding of this study is that aortic endothelial cells respond to several bacterial constituents that stimulate TLR2, leading to induction of Weibel-Palade body exocytosis through a MyD88-dependent mechanism without *de novo* protein synthesis. During this process, release of VWF and externalization of P-selectin were induced, by which rolling and adhesion of platelets and leukocytes and thrombus formation in the local vessel walls may be promoted (34, 35). The pathological role of this phenomenon *in vivo* may be supported by the observations in mouse experiments, *i.e.* slight increases of local leukocyte-endothelial interaction after LTA administration (36) and soluble P-selectin level in serum after administration of the synthetic




FIGURE 5. PLC- γ mediation of TLR2-activated Weibel-Palade body exocytosis and NF- κ B activation. **A**, confluent HAECs were pretreated with 20 μ M BAPTA-AM for 30 min or incubated in Ca^{2+} -free media. Then the cells were washed and stimulated with 10 μ g/ml LTA for 60 min in Ca^{2+} -free media. The amounts of VWF released into the media were measured by ELISA. Each value is the mean \pm S.D. ($n = 3$). *, $p < 0.01$. **B**, HAECs were pretreated with 10 μ M U-73122 for 30 min and then washed and stimulated with Pam₂CSK₄ (10 μ g/ml), FSL-1 (1 μ g/ml), MALP-2 (1 μ g/ml), LTA (10 μ g/ml), and A23187 (1 μ M) for 60 min. The amounts of VWF released into the media were measured by ELISA. Each value is the mean \pm S.D. ($n = 3$). *, versus vehicle group, $p < 0.01$. **C**, HAECs transfected with MyD88- or IRAK1-specific or control siRNA were stimulated with 10 μ g/ml LTA for 90 min. Immunoblot analysis was then performed to examine the expression of phosphorylated PLC- γ 1 (Y783) and total PLC- γ 1 (left). Immunoreactive bands were quantified by a densitometer (right). Results are expressed as means \pm S.D. of three independent experiments. *, versus control group, $p < 0.01$. **D**, HAECs were pretreated with 10 μ M U-73122 for 30 min and then washed and stimulated with Pam₂CSK₄ (10 μ g/ml), FSL-1 (1 μ g/ml), MALP-2 (1 μ g/ml), LTA (10 μ g/ml), and A23187 (1 μ M) for 4 h. The amounts of IL-8 released into the media were measured by ELISA. Each value is the mean \pm S.D. ($n = 3$). *, versus vehicle group, $p < 0.01$. **E**, HAECs were pretreated with 10 μ M U-73122 for 30 min and then washed and stimulated with 10 μ g/ml LTA for the indicated period. Immunoblot analysis was then performed to examine the expression of I κ B α and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

lipopeptide FSL-1.³ Sequentially or simultaneously, both PLC- γ and IRAK1-mediated signaling pathways activate NF- κ B, by which production of various proinflammatory cyto-




FIGURE 6. Regulation of TLR2-mediated Weibel-Palade body exocytosis. **A** and **B**, HAECs were treated with IFN- γ for 12 h. Surface TLR2 expression was detected by flow cytometry (**A**). The shaded histogram indicates cells stained with control antibody. The cells were washed and stimulated with Pam₂CSK₄ (10 μ g/ml), FSL-1 (1 μ g/ml), MALP-2 (1 μ g/ml), and LTA (10 μ g/ml) for 60 min. The amounts of VWF released into the media were measured by ELISA (**B**). Each value is the mean \pm S.D. ($n = 3$). *, versus vehicle group, $p < 0.05$. **C** and **D**, HAECs were incubated under laminar flow for 12 h. Surface TLR2 expression was detected by flow cytometry (**C**). The shaded histogram indicates cells stained with control antibody. The cells were then stimulated with Pam₂CSK₄ (10 μ g/ml), FSL-1 (1 μ g/ml), MALP-2 (1 μ g/ml), and LTA (10 μ g/ml) for 60 min. The amounts of VWF released into the media were measured by ELISA (**D**). Each value is the mean \pm S.D. ($n = 3$). *, versus static group, $p < 0.05$.

kines, and expression of adhesion molecules such as ICAM-1 are induced to promote adherence and activation of platelets and leukocytes (37). The delayed Weibel-Palade body exocytosis with *de novo* protein synthesis is further activated in the cells. Therefore, endothelial TLR2 may be able to function as a primary initiator and a modulator of artery inflammation through these early-phase endothelial responses after recognition of cognate agonists.

We investigated the responsiveness of HAECs toward common bacterial constituents. For the TLR2 agonists, we prepared several compounds that have already been proposed to function as TLR2 agonists, because TLR2 forms a complicated recognition system and because human endothelial cells from different vascular beds show different degrees of responsiveness to TLR2 agonists (32, 38, 39). Unexpectedly, PGN, unlike other TLR2 agonists, could not activate either Weibel-Palade body exocytosis or IL-8 production (Figs. 1D and 3A). The issue of recognition of PGN by TLR2 is still controversial. The existence of an intracellular receptor for PGN (NOD2) further complicates this matter. However, Gupta's group recently concluded that PGN is in fact recognized by TLR2 by showing that muramidase treatment of PGN abolished the TLR2-stimulating activity (8). We showed that recognition of our PGN was at least dependent on TLR2 (Fig. 3A). It has been shown that PGN directly binds TLR2 *per se* (40), whereas bacterial lipopeptides

³ T. Into, Y. Kanno, J.-I. Dohkan, M. Nakashima, M. Inomata, K.-I. Shibata, C. J. Lowenstein, and K. Katsushita, unpublished data.

TLR2 Mediates Weibel-Palade Body Exocytosis

are thought to directly interact with TLR2-associated molecules such as CD14 and LBP but not with TLR2 *per se* (7, 41, 42), suggesting the existence of different ligand-recognition mechanisms by TLR2. Furthermore, a novel family of PGN-binding proteins such as peptidoglycan recognition proteins has been found (43) and might enable discrimination of PGN from other TLR2 agonists. Thus, PGN may be recognized by a TLR2 recognition system different from that for LTA and lipoproteins/lipopeptides. Collectively, HAECs express functional TLR2 to respond to several TLR2 agonists, including lipopeptides and LTA, but may lack a PGN-recognition system resulting in an inability to respond to PGN. Moreover, aortic endothelial cells may particularly recognize diacylglyceride-containing bacterial lipid derivatives (LTA and bacterial lipopeptides), recognition of which has recently been reported to depend on TLR6 and CD36 (11).

We also showed that the TLR4 agonist LPS did not activate Weibel-Palade body exocytosis (Fig. 1D). Although the reason for this is not clear, several lines of evidence obtained in previous studies may provide an explanation. For example, TLR4 expression has been reported to localize intracellularly in artery endothelial cells (44). This observation suggests that TLR4 in artery endothelial cells may be lacking in induction of phospholipid-dependent signaling events, including PLC γ activation, which are commonly intrinsic to the signaling receptors spanning the cell membrane. Further investigation is needed to determine the reason.

Several properties of endothelial TLR2 have been proposed to be involved in the development of atherosclerosis. First, endothelial TLR2 expression is enhanced by proinflammatory stimuli, such as TNF- α , IFN- γ , and LPS (32), and by SP-1-dependent machinery in areas of disturbed blood flow such as lesion predilection within the aortic tree and heart (33). The expression level of TLR2 is indeed increased in an atherosclerotic lesion in humans (45). Furthermore, a recent study has revealed that complete deficiency of TLR2 in atherosclerosis-prone LDLR-null mice leads to an apparent reduction in the formation of lesions (46). Proinflammatory signaling pathways downstream of TLR2 have been thought to be activated through TIRAP/Mal, MyD88, IRAK-1, and TRAF6 in endothelial cells. Other pathways involving PI3K and the downstream protein kinase Akt/PKB (47), the Rho family GTPase Rac1 (48), and the redox-activated mitogen-activated protein kinase kinase kinase ASK1 (49) also link TLR2 signaling to the NF- κ B pathway. In this study, we showed that PLC γ also mediated the NF- κ B pathway downstream of TLR2 in HAECs, although involvement of PLC γ in the TLR2 proinflammatory signaling has been described in several reports (27, 50). Because PLC γ isoforms are thought to be activated by both generation of phosphatidylinositol 3,4,5-triphosphate by PI3K and tyrosine phosphorylation, we found the latter process downstream of TLR2 was dependent on MyD88 but not IRAK-1 (Fig. 5C). Recent studies have suggested a linkage of TLRs and tyrosine kinases, including Syk via MyD88-STAP-2 interaction (51) and Btk via direct interaction with TIR domain (52), both of which have been shown to activate PLC γ isoforms. Moreover, Btk-induced phosphorylation of TIRAP/Mal has recently been reported to play an important role in TLR signal transduction




FIGURE 7. The proposed schematic for TLR2 regulation of early-phase inflammatory signaling in human aortic endothelial cells.

(53), which may occur at a phosphatidylinositol diphosphate-rich membrane compartment after recruitment of MyD88 to membrane-localized TIRAP/Mal (54). A schematic of signaling pathways proposed here is shown in Fig. 7.

Endothelial activation by several proinflammatory agents has been shown to increase endothelial responsiveness toward TLR2 agonists via up-regulation of TLR2 expression (32). Increased endothelial TLR2 expression increased the magnitude of TLR2-mediated exocytosis of Weibel-Palade bodies (Fig. 6B) and endothelial responses (38), suggesting enhanced responsiveness of endothelial cells to pathogens in inflamed lesions. In contrast, fluid shear decreased the magnitude of TLR2 ligand-stimulated Weibel-Palade body exocytosis (Fig. 6D). Physiological fluid shear stress has been suggested to have atheroprotective effects *in vivo*, because atherosclerosis preferentially occurs in an area of disturbed flow or a low level of shear stress, whereas regions with steady laminar flow and physiological shear stress are protected. Disturbed flow or a low level of shear stress has been reported to regulate expression of various regulatory molecules of endothelial activation, by which atherosclerotic processes may be accelerated in the sites. These observations are consistent with the previous finding that physiological fluid shear stress decreases endothelial TLR2 expression via impaired activity of the transcriptional factor SP1 (33). Thus, our results raise the possibility that bacterial constituent-induced Weibel-Palade body exocytosis can be physiologically or pathologically regulated in particular circumstances of the vessel wall.

In conclusion, our study focused on endothelial exocytosis induced by bacterial pathogens and showed a linkage between endothelial innate recognition of pathogens and early-phase endothelial inflammatory responses. Our results may provide a new insight into the role of endothelial TLR2 in the initiation and modulation of vascular inflammation or atherogenic responses.

REFERENCES

1. Lowenstein, C. J., Morrell, C. N., and Yamakuchi, M. (2005) *Trends Cardiovasc. Med.* 15, 302–308
2. Rondaj, M. G., Bierings, R., Kragt, A., van Mourik, J. A., and Voorberg, J.

- (2006) *Arterioscler. Thromb. Vasc. Biol.* **26**, 1002–1007
3. Danesh, J. (1999) *Am. Heart J.* **138**, S434–S437
 4. Desvarieux, M., Demmer, R. T., Rundek, T., Boden-Albala, B., Jacobs, D. R., Jr., Sacco, R. L., and Papapanou, P. N. (2005) *Circulation* **111**, 576–582
 5. Akira, S., and Takeda, K. (2004) *Nat. Rev. Immunol.* **4**, 499–511
 6. Kirschning, C. J., and Schumann, R. R. (2002) *Curr. Top. Microbiol. Immunol.* **270**, 121–144
 7. Schroder, N. W., Morath, S., Alexander, C., Hamann, L., Hartung, T., Zahring, U., Gobel, U. B., Weber, J. R., and Schumann, R. R. (2003) *J. Biol. Chem.* **278**, 15587–15594
 8. Dziarski, R., and Gupta, D. (2005) *Infect. Immun.* **73**, 5212–5216
 9. Reed, K. A., Hobert, M. E., Kolenda, C. E., Sands, K. A., Rathman, M., O'Connor, M., Lyons, S., Gewirtz, A. T., Sansonetti, P. J., and Madara, J. L. (2002) *J. Biol. Chem.* **277**, 13346–13353
 10. Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J., and Tobias, P. S. (2000) *J. Immunol.* **165**, 5780–5787
 11. Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zahring, U., and Beutler, B. (2005) *Nature* **433**, 523–527
 12. Jeannin, P., Bottazzi, B., Sironi, M., Doni, A., Rusnati, M., Presta, M., Maina, V., Magistrelli, G., Haeuw, J. F., Hoeffel, G., Thieblemont, N., Corvaia, N., Garlanda, C., Delneste, Y., and Mantovani, A. (2005) *Immunity* **22**, 551–560
 13. Mullaly, S. C., and Kubes, P. (2004) *Circ. Res.* **95**, 657–659
 14. Tobias, P., and Curtiss, L. K. (2005) *J. Lipid Res.* **46**, 404–411
 15. Michelsen, K. S., Doherty, T. M., Shah, P. K., and Arditi, M. (2004) *J. Immunol.* **173**, 5901–5907
 16. Hoffmann, P., Heine, S., Schade, U. F., Loppnow, H., Ulmer, A. J., Flad, H. D., Jung, G., and Bessler, W. G. (1988) *Immunobiology* **177**, 158–170
 17. Fujita, M., Into, T., Yasuda, M., Okusawa, T., Hamahira, S., Kuroki, Y., Eto, A., Nisizawa, T., Morita, M., and Shibata, K. (2003) *J. Immunol.* **171**, 3675–3683
 18. Shibata, K., Hasebe, A., Into, T., Yamada, M., and Watanabe, T. (2000) *J. Immunol.* **165**, 6538–6544
 19. Muhlrath, P. F., Kiess, M., Meyer, H., Sussmuth, R., and Jung, G. (1997) *J. Exp. Med.* **185**, 1951–1958
 20. Into, T., Kiura, K., Yasuda, M., Kataoka, H., Inoue, N., Hasebe, A., Takeda, K., Akira, S., and Shibata, K. (2004) *Cell Microbiol.* **6**, 187–199
 21. Matsushita, K., Morrell, C. N., Cambien, B., Yang, S. X., Yamakuchi, M., Bao, C., Hara, M. R., Quick, R. A., Cao, W., O'Rourke, B., Lowenstein, J. M., Pevsner, J., Wagner, D. D., and Lowenstein, C. J. (2003) *Cell* **115**, 139–150
 22. Dimmeler, S., Haendeler, J., Rippmann, V., Nehls, M., and Zeiher, A. M. (1996) *FEBS Lett.* **399**, 71–74
 23. Doran, K. S., Engelson, E. J., Khosravi, A., Malsey, H. C., Fedtke, I., Equils, O., Michelsen, K. S., Arditi, M., Peschel, A., and Nizet, V. (2005) *J. Clin. Invest.* **115**, 2499–2507
 24. Bempohl, D., Halle, A., Freyer, D., Dagand, E., Braun, J. S., Bechmann, I., Schroder, N. W., and Weber, J. R. (2005) *J. Clin. Invest.* **115**, 1607–1615
 25. Talreja, J., Kabir, M. H., Filla, M. B., Stechschulte, D. J., and Dileepan, K. N. (2004) *Immunology* **113**, 224–233
 26. Xu, Y., Tao, X., Shen, B., Horng, T., Medzhitov, R., Manley, J. L., and Tong, L. (2000) *Nature* **408**, 111–115
 27. Chun, J., and Prince, A. (2006) *J. Immunol.* **177**, 1330–1337
 28. Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C., and Ogawa, H. (2002) *J. Clin. Invest.* **109**, 1351–1359
 29. Bae, Y. S., Cantley, L. G., Chen, C. S., Kim, S. R., Kwon, K. S., and Rhee, S. G. (1998) *J. Biol. Chem.* **273**, 4465–4469
 30. Davis, C. N., Mann, E., Behrens, M. M., Gaidarova, S., Rebek, M., Rebek, J., Jr., and Bartfai, T. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 2953–2958
 31. Law, C. L., Chandran, K. A., Sidorenko, S. P., and Clark, E. A. (1996) *Mol. Cell Biol.* **16**, 1305–1315
 32. Faure, E., Thomas, L., Xu, H., Medvedev, A., Equils, O., and Arditi, M. (2001) *J. Immunol.* **166**, 2018–2024
 33. Duzendorfer, S., Lee, H. K., and Tobias, P. S. (2004) *Circ. Res.* **95**, 684–691
 34. Andre, P., Denis, C. V., Ware, J., Saffaripour, S., Hynes, R. O., Ruggeri, Z. M., and Wagner, D. D. (2000) *Blood* **96**, 3322–3328
 35. Massberg, S., Brand, K., Gruner, S., Page, S., Muller, E., Muller, I., Bergmeier, W., Richter, T., Lorenz, M., Konrad, I., Nieswandt, B., and Gawaz, M. (2002) *J. Exp. Med.* **196**, 887–896
 36. Yipp, B. G., Andonegui, G., Howlett, C. J., Robbins, S. M., Hartung, T., Ho, M., and Kubes, P. (2002) *J. Immunol.* **168**, 4650–4658
 37. Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., and Maniatis, T. (1995) *FASEB J.* **9**, 899–909
 38. Bulut, Y., Faure, E., Thomas, L., Equils, O., and Arditi, M. (2001) *J. Immunol.* **167**, 987–994
 39. Faure, E., Equils, O., Sieling, P. A., Thomas, L., Zhang, F. X., Kirschning, C. J., Polentarutti, N., Muzio, M., and Arditi, M. (2000) *J. Biol. Chem.* **275**, 11058–11063
 40. Iwaki, D., Mitsuzawa, H., Murakami, S., Sano, H., Konishi, M., Akino, T., and Kuroki, Y. (2002) *J. Biol. Chem.* **277**, 24315–24320
 41. Manukyan, M., Triantafyllou, K., Triantafyllou, M., Mackie, A., Nilsen, N., Espevik, T., Wiesmuller, K. H., Ulmer, A. J., and Heine, H. (2005) *Eur. J. Immunol.* **35**, 911–921
 42. Schroder, N. W., Heine, H., Alexander, C., Manukyan, M., Eckert, J., Hamann, L., Gobel, U. B., and Schumann, R. R. (2004) *J. Immunol.* **173**, 2683–2691
 43. Dziarski, R., and Gupta, D. (2006) *Cell Microbiol.* **8**, 1059–1069
 44. Duzendorfer, S., Lee, H. K., Soldau, K., and Tobias, P. S. (2004) *FASEB J.* **18**, 1117–1119
 45. Edfeldt, K., Swedenborg, J., Hansson, G. K., and Yan, Z. Q. (2002) *Circulation* **105**, 1158–1161
 46. Mullick, A. E., Tobias, P. S., and Curtiss, L. K. (2005) *J. Clin. Invest.* **115**, 3149–3156
 47. Martin, M., Schifferle, R. E., Cuesta, N., Vogel, S. N., Katz, J., and Michalek, S. M. (2003) *J. Immunol.* **171**, 717–725
 48. Arbibe, L., Mira, J. P., Teusch, N., Kline, L., Guha, M., Mackman, N., Godowski, P. J., Ulevitch, R. J., and Knaus, U. G. (2000) *Nat. Immunol.* **1**, 533–540
 49. Into, T., and Shibata, K. (2005) *Cell Microbiol.* **7**, 1305–1317
 50. Lee, C. W., Chien, C. S., and Yang, C. M. (2004) *Am. J. Physiol.* **286**, L921–L930
 51. Sekine, Y., Yurnioka, T., Yamamoto, T., Muromoto, R., Imoto, S., Sugiyama, K., Oritani, K., Shimoda, K., Minoguchi, M., Akira, S., Yoshimura, A., and Matsuda, T. (2006) *J. Immunol.* **176**, 380–389
 52. Horwood, N. J., Page, T. H., McDaid, J. P., Palmer, C. D., Campbell, J., Mahon, T., Brennan, F. M., Webster, D., and Foxwell, B. M. (2006) *J. Immunol.* **176**, 3635–3641
 53. Gray, P., Dunne, A., Brikos, C., Jefferies, C. A., Doyle, S. L., and O'Neill, L. A. (2006) *J. Biol. Chem.* **281**, 10489–10495
 54. Kagan, J. C., and Medzhitov, R. (2006) *Cell* **125**, 943–955
 55. Nakao, Y., Funami, K., Kikkawa, S., Taniguchi, M., Nishiguchi, M., Fukumori, Y., Seya, T., and Matsumoto, M. (2005) *J. Immunol.* **174**, 1566–1573